CASP1 and endometrial cancer: We observed LDH and IL-1β release to be increased in hydrogen-treated endometrial cancer cells that were upregulated by LPS and nigericin or downregulated by ROS, NLRP3, or the caspase-1 inhibitor (Fig. 6).